NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 1 November 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Iftab Akram Present for all items
4. Dr Alex Cale Items 1 to 4.2.2
5. Michael Chambers Present for all items
6. Dr Prithwiraj Das Present for all items
7. Chamkhor Dhillon Present for all items
8. Dr David Foreman Present for all items
9. Dr Rob Forsyth Present for all items
10. Dr Pedro Saramago Goncalves Present for all items
11. Dr Natalie Hallas Present for all items
12. John Hampson Present for all items
13. Dr Nigel Langford Items 1 to 5.1.3
14. Dr Steven Lloyd Present for all items
15. Iain McGowan Present for all items
16. Ugochi Nwulu Present for all items
17. Stella O’Brien Present for all items
18. Professor Subhash Pokhrel Present for all items
19. Professor Andrew Renehan Present for all items
20. Dr Arpit Srivastava Present for all items
21. Professor Matthew Stevenson Present for all items
22. Professor Paul Tappenden Present for all items

**NICE staff (key players) present**

Ross Dent, Associate Director Items 1 to 4.2.2

Jasdeep Hayre, Associate Director Items 4.1.3 to 4.2.2

Linda Landells, Associate Director Items 5 to 5.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Celia Mayers, Project Manager Items 5.2 to 5.2.2

Kate Moore, Project Manager Items 5 to 5.2.2

Alex Filby, Heath Technology Assessment Adviser Items 1 to 4.2.2

Louise Crathorne, Heath Technology Assessment Adviser Present for all items

Catie Parker, Heath Technology Assessment Analyst Items 1 to 4.2.2

Albany Chandler, Heath Technology Assessment Analyst Present for all items

Benjamin Gregory, Business Analyst, RIA Present for all items

Anna Sparshatt, Senior Medical Editor Items 1 to 4.1.3

Olivia Havercroft, Senior Medical Editor Items 5 to 5.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 1 to 4.2.2

Mohammed Towhasir, Administrator, TA Items 5 to 5.2.2

**NICE staff (observers) present**

Vicky Kelly, Heath Technology Assessment Adviser Items 1 to 4.2.2

Sally Doss, Heath Technology Assessment Adviser Items 1 to 4.2.2

Lewis Ralph, Heath Technology Assessment Analyst Items 1 to 4.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 1 to 4.2.2

Anne Murray-Cota, Heath Technology Assessment Analyst Items 4 to 4.2.2

Emily Eaton-Turner, Technical Adviser, Commercial Liaison team, Items, 1 to 4.2.2

Neha Jiandani, Technical Analyst, Commercial Liaison team, Items 1 to 4.2.2

Catrin Austin, Technical Analyst, Managed Access team, Items 1 to 4.2.2

Thomas Palmer, Technical Analyst, Interventional Procedures team, Items 1 to 4.2.2

Georgina Fletcher, Media Relations Executive Present for all items

George Millington, Heath Technology Assessment Analyst Items 1 to 4.2.2

Liam Murray, Administrator, COT Items 1 to 4.2.2

External assessment group representatives present

Dwayne Boyers, Aberdeen HTA Group Items 1 to 4.1.3

Neil Scott, Aberdeen HTA Group Items 1 to 4.1.3

Emma Maund, Southampton Health Technology Assessment Centre (SHTAC), Items 5 to 5.1.3

Keith Cooper, Southampton Health Technology Assessment Centre (SHTAC), Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Dr Sridhar Chaganti, Consultant Haematologist, clinical expert nominated by the Royal College of Pathologists, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Robert Cross, Patient expert, nominated by Anthony Nolan, 1 to 4.1.3

Rebecca Hallam, Patient expert, nominated by Anthony Nolan, Items 1 to 4.1.3

Dr Andrew McMillan, Consultant Haematologist, clinical expert nominated by NHSE, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Professor Stephen O’Brien welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. Committee welcomed newly appointed member Arpit Srivastava to his first TA committee meeting.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 4 October 2022.

### Appraisal of axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Kite, a Gilead company
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Stella O’Brien declared personal interests as she is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK’s research and academic communities. Although CAR-T therapies are an example of ATMPs, she has not contributed to work on CAR-T therapies with this group. It was agreed her declaration would not prevent Stella from participating in discussions on this appraisal.
* Nominated clinical expert Dr Andrew McMillan declared financial interests as he has worked indirectly for NHSE as Chair of the National CAR-T cell Clinical Panel for Lymphoma and has received honoraria and travel sponsorship from Roche and Amgen which have other non-CAR-T competing products for the treatment of Lymphoma. It was agreed his declarations would not prevent Dr McMillan from providing expert advice to the committee.
* Nominated clinical expert Dr Sridhar Chaganti declared financial interests as he has received honoraria for consultancy, advisory boards, speaker fees or meeting support from Kite-Gilead, Novartis, Celgene-BMS, Incyte, Roche, Takeda, Atarabio and Orion Pharma. It was agreed his declarations would not prevent Dr Chaganti from providing expert advice to the committee.
* Nominated patient expert Robert Cross declared indirect financial interests as his nominating organisation Anthony Nolan has received funding from Kite/Gilead to conduct a CAR-T patient experience study and for attendance at an advisory board and an online seminar. It was agreed his declarations would not prevent Robert from providing expert advice to the committee.
* Nominated patient expert Rebecca Hallam declared indirect financial interests as her nominating organisation Anthony Nolan has received funding from Kite/Gilead to conduct a CAR-T patient experience study and for attendance at an advisory board and an online seminar. She also declared direct financial interests as she received payment for presenting the role of ambulatory care in the delivery of CAR-T cell therapy for Novartis at a study evening in November 2021 and payment to review the BMT information in the booklet for Cancer Research UK. It was agreed her declarations would not prevent Rebecca from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Professor Matt Stevenson, John Hampson, and Ugochi Nwulu.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10580>.

### Appraisal of Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited NHSE expert, external assessment group representatives, members of the public and company representatives from Roche Products
     2. The chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial interests as he has co-ordinated a training programme (with the University of Utrecht) for Roche (submitting company) on Real World Evidence, which did not involve specific consideration of Roche's products and he has participated in an advisory panel for Pfizer (possible comparator) in an unrelated disease area (prostate cancer). It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial interests as he has carried out paid advisory boards with Roche in an unrelated area - multiple sclerosis. It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
* No further interests were declared for this item
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10785>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 6 December 2022 and will start promptly at 09.30.